Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

NRX Pharmaceuticals, Inc. NRXP

· Materials · Pharmaceutical Preparations

FY2025 10-K, filed 2026-03-23
SEC EDGAR

Filing evidence summary

Caution evidenceCoverage 3/5 core metrics

Debt/equity is shown as not meaningful rather than as a negative leverage ratio.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Shareholders' equity was non-positive

    Debt/equity is shown as not meaningful rather than as a negative leverage ratio.

    Why this surfaced

    Same-period reported shareholders' equity was zero or negative; review the balance sheet and capital structure. Period end 2025-12-31.

  • 5 filing risk checks flagged

    Flagged areas: Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

Core trend metrics

Latest annual operating margin
-1324.4%
as of 2025-12-31
Debt / equity
N/M
as of 2025-12-31
ROIC snapshot
-129.5%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

5of 8 rule-based checks flagged
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-23prior period 2024-12-31 from the same filingView filing
By product or service
Revenue
  • Therapy$854K
    69.7%
    no prior
  • Procedures$371K
    30.3%
    no prior

Members sum to the consolidated $1.23M for this period.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-15prior period 2025-03-31 from the same filingView filing
  • Therapy$760K
    71.2%
    no prior
  • Procedures$308K
    28.8%
    no prior

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,058 US-listed filers · 782 in Materials
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$1M
4thof 3,301
bottom third
11thof 522
bottom third
Operating margin
operating income ÷ revenue
-1324.4%
6thof 2,819
bottom third
18thof 483
bottom third
Net margin
net income ÷ revenue
-2336.5%
4thof 3,263
bottom third
14thof 518
bottom third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
18.6%
17thof 2,895
bottom third
36thof 476
middle third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
48 days
52ndof 2,398
middle third
56thof 387
middle third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

Not available for NRXP yet: Earnings-quality fields arrive with this issuer's next re-crawl (sec_screen_v6)..

Point-in-time ledger

Not available for NRXP yet: The point-in-time ledger arrives with this issuer's next re-crawl (sec_screen_v6)..

Notes by disclosure type

Not available for NRXP yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.